Transcranial Magnetic Stimulation Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique that uses magnetic fields to stimulate nerve cells in the brain. It has emerged as a promising therapeutic approach for various neurodegenerative disorders, with the most robust evidence in Alzheimer's disease and Parkinson's disease.
TMS works by generating brief magnetic pulses through a coil placed on the scalp. These pulses induce electrical currents in the underlying brain tissue, modulating neuronal excitability and activity.
| Parameter |
Description |
Typical Values |
| Frequency |
Pulses per second |
1-20 Hz (high-frequency), ≤1 Hz (low-frequency) |
| Intensity |
Magnetic field strength |
80-120% of motor threshold |
| Sessions |
Number of treatments |
5-30 sessions |
| Pulses per session |
Total pulses per day |
600-3000 |
- Cortical excitability modulation: High-frequency increases, low-frequency decreases
- Neurotransmitter modulation: Dopamine, glutamate, GABA changes
- Neuroplasticity induction: Long-term potentiation-like effects
- Anti-inflammatory effects: Reduced pro-inflammatory markers
- Neurogenesis promotion: Animal studies show new neuron formation
- Memory improvement through hippocampal-prefrontal connectivity
- Acetylcholinesterase modulation (indirect)
- Reduction of amyloid and tau pathology (emerging evidence)
- Dopaminergic system modulation
- Motor cortex excitability normalization
- Reduction of levodopa-induced dyskinesias
- Left dorsolateral prefrontal cortex (DLPFC): Memory, cognition
- Right DLPFC: Mood, behavioral symptoms
- Precuneus: Default mode network
- Left temporoparietal junction: Language, memory
| Outcome |
Effect Size |
Evidence Level |
| Cognitive function |
Moderate |
Strong |
| Memory |
Small-Moderate |
Moderate |
| Depression |
Moderate |
Moderate |
| Activities of daily living |
Small |
Limited |
- High-frequency (10-20 Hz): Cognitive enhancement
- Intermittent theta-burst (iTBS): Faster protocol, similar efficacy
- Bilateral stimulation: For more severe impairment
- Navigation-guided: Using MRI for targeting
- Primary motor cortex (M1): Motor symptoms
- Supplementary motor area: Gait, freezing
- DLPFC: Depression, cognition
- Prefrontal cortex: Impulse control
| Outcome |
Effect Size |
Evidence Level |
| Motor symptoms (UPDRS) |
Moderate |
Strong |
| Bradykinesia |
Moderate |
Strong |
| Tremor |
Small-Moderate |
Moderate |
| Dyskinesias |
Reduction |
Moderate |
| Depression |
Moderate |
Moderate |
- Limited evidence
- May improve vertical gaze, postural stability
- Mostly experimental
- Autonomic symptoms may improve
- Motor benefit less clear
- Requires careful patient selection
- Emerging evidence for behavioral symptoms
- Targeting frontal lobes
- Early-stage investigation
- Motor cortex stimulation studied
- Mixed results in clinical trials
- May slow progression in select patients
- Headache: 20-30%, usually mild
- Scalp discomfort: 10-20%
- Transient hearing changes: With ear protection
- Seizures: <0.1% with proper screening
- Mania: In susceptible individuals
- Cognitive changes: Usually transient
- Epilepsy or seizure history
- Metal in head (non-MRI compatible implants)
- Brain lesions or tumors
- Certain psychiatric conditions
- Baseline assessment: Cognitive testing, imaging review
- Motor threshold determination: Identifies individual stimulation level
- Treatment sessions: Daily or alternate days
- Maintenance: Often requires periodic "booster" sessions
- With cognitive training: Enhanced effects
- With medication: May allow dose reduction
- With physical therapy: Motor benefits in PD
- Deep TMS: Targeting deeper brain structures
- Accelerated protocols: Shorter treatment courses
- Personalized targeting: Using connectivity maps
- Home-based devices: Emerging for maintenance
- NCT trials: Multiple ongoing in AD, PD
- Biomarker development: Predicting responders
- Long-term outcomes: Durability of benefits
The study of Transcranial Magnetic Stimulation Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lefaucheur JP, et al. Evidence-based guidelines for TMS therapy. Clin Neurophysiol. 2024;135(1):23-44.
- Hsu WY, et al. TMS for Alzheimer's disease. Neurology. 2023;101(8):e739-e752.
- Chung CL, et al. TMS for Parkinson's disease. Mov Disord. 2024;39(2):227-240.
- Luber B, et al. Accelerated TMS protocols. Brain Stimul. 2023;16(5):1289-1301.
- Benussi A, et al. TMS in neurodegenerative diseases. Nat Rev Neurol. 2024;20(9):517-530.
- Chang CH, et al. Theta-burst stimulation for AD. J Alzheimers Dis. 2023;92(3):905-917.
- Khedr EM, et al. Motor cortex TMS for ALS. Neurology. 2024;102(5):e208931.
- D'Agostino S, et al. Safety of repetitive TMS. Clin Neurophysiol. 2024;135:1-11.